サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1513882

抗感染症薬の世界市場

Anti-Infectives

出版日
ページ情報
英文 116 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.82円
抗感染症薬の世界市場
出版日: 2024年07月17日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 116 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

抗感染症薬の世界市場は2030年までに2,313億米ドルに達する見込み

2023年に1,518億米ドルと推定される抗感染症薬の世界市場は、分析期間2023～2030年にCAGR 6.2%で成長し、2030年には2,313億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである抗ウイルス薬は、CAGR 7.3%を記録し、分析期間終了時には1,171億米ドルに達すると予測されます。抗真菌薬セグメントは、分析期間中にCAGR 4.9%の成長が見込まれます。

米国市場は394億米ドル、中国はCAGR 10.1％で成長すると予測

米国の抗感染症薬市場は2023年に394億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに576億米ドルの市場規模に達すると予測され、分析期間2023～2030年のCAGRは10.1%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ3.3%と4.7%と予測されています。欧州では、ドイツがCAGR約4.2％で成長すると予測されています。

抗感染症薬-主要動向と促進要因

抗感染症薬は現代医療の要であり、細菌、ウイルス、真菌、寄生虫による感染症に対処するための多様な薬剤で構成されています。この広範なカテゴリーには、抗生物質、抗ウイルス薬、抗真菌薬、抗寄生虫薬が含まれ、それぞれが様々な感染症の治療に重要な役割を果たしています。抗感染症薬の開発と使用は、罹患率と死亡率を大幅に減少させ、かつては致命的と考えられていた病気の治療に革命をもたらしました。過去数十年にわたり、バイオテクノロジーと製薬研究の革新は、新規化合物の発見と既存薬の改良につながり、その有効性を向上させ、副作用を減少させました。抗生物質耐性という現在進行中の課題は、依然としてこのセグメントで重要な焦点となっています。抗生物質の乱用や誤用は、病原体の薬剤耐性株の出現を加速させ、公衆衛生に深刻な脅威をもたらしています。そのため、研究開発への多額の投資は、耐性感染と闘うための新しい抗生物質や、バクテリオファージ、モノクローナル抗体、免疫療法などの代替療法の発見に向けられています。

世界の健康動向と感染症の疫学は、抗感染症薬市場に大きな影響を与えています。COVID-19の原因である新型コロナウイルスのような新しい病原体の出現は、強固な抗感染戦略の必要性を強調しています。大規模なワクチン接種プログラム、公衆衛生への取り組み、衛生環境の改善は、感染症の制御に重要な役割を果たしてきました。しかし、感染症の脅威は絶えることがないため、抗感染症薬の継続的な進歩が必要です。診断技術の急速な進歩も、感染症の迅速かつ正確な発見を可能にしています。これにより、タイムリーで適切な治療が可能となり、感染症の負担が軽減されています。さらに、グローバリゼーション、国際的な旅行や貿易の増加により、感染症が国境を越えて伝播するリスクが高まっています。高度な監視システムや国際協力を通じて感染症の発生を監視・制御する取り組みは、市場のダイナミックな性質と絶え間ないイノベーションの必要性をさらに際立たせています。

抗感染症薬市場の成長は、いくつかの要因によってもたらされます。高性能・スクリーニング、人工知能、ゲノム研究など、創薬・薬剤開発における技術の進歩は、潜在的な抗感染症薬の同定を加速させています。これらの技術は、病原体をより正確に標的化することを可能にし、薬剤の有効性を向上させ、耐性菌発生の可能性を減少させる。がん、糖尿病、HIVなど、感染症への感受性を高める慢性疾患や免疫不全の有病率が上昇しているため、効果的な抗感染症治療への需要が高まっています。消費者の行動も重要な役割を果たしており、健康やウェルネスに対する意識の高まりや積極的なアプローチが市場拡大に寄与しています。新興市場における医療インフラの拡大と医療サービスへのアクセスの向上が、抗感染症薬の消費をさらに押し上げています。迅速な承認や抗菌薬耐性研究への資金提供といった規制上のインセンティブが、この市場の成長を支えています。製薬会社、学術機関、政府機関の連携により、このセグメントにおける技術革新と開発が促進され、新規で効果的な抗感染症薬の継続的なパイプラインが確保されています。また、官民パートナーシップや世界ヘルスイニシアチブは、アンメットニーズへの対応に不可欠であり、世界の感染症対策に不可欠な医薬品の開発と流通を促進しています。

調査対象企業の例（注目の17社）

  • Allergan PLC
  • Bayer AG
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche AG
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis International AG
  • Pfizer, Inc.
  • Sanofi

目次

第1章 調査手法

第2章 エグゼクティブ概要

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の展望

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他の欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他のアジア太平洋
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他のラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他の中東
  • アフリカ

第4章 競合

目次
Product Code: MCP-6156

Global Anti-Infectives Market to Reach US$231.3 Billion by 2030

The global market for Anti-Infectives estimated at US$151.8 Billion in the year 2023, is expected to reach US$231.3 Billion by 2030, growing at a CAGR of 6.2% over the analysis period 2023-2030. Anti-Viral Drugs, one of the segments analyzed in the report, is expected to record a 7.3% CAGR and reach US$117.1 Billion by the end of the analysis period. Growth in the Anti-Fungal Drugs segment is estimated at 4.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$39.4 Billion While China is Forecast to Grow at 10.1% CAGR

The Anti-Infectives market in the U.S. is estimated at US$39.4 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$57.6 Billion by the year 2030 trailing a CAGR of 10.1% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.3% and 4.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.2% CAGR.

Anti-Infectives - Key Trends and Drivers

Anti-infectives are a cornerstone of modern medicine, comprising a diverse range of drugs designed to combat infections caused by bacteria, viruses, fungi, and parasites. This broad category includes antibiotics, antivirals, antifungals, and antiparasitics, each playing a crucial role in treating various infectious diseases. The development and use of anti-infectives have significantly reduced morbidity and mortality rates, revolutionizing the treatment of diseases that were once considered deadly. Over the past few decades, innovations in biotechnology and pharmaceutical research have led to the discovery of novel compounds and the enhancement of existing drugs, improving their efficacy and reducing side effects. The ongoing challenge of antibiotic resistance remains a significant focus within this field. The overuse and misuse of antibiotics have accelerated the emergence of drug-resistant strains of pathogens, posing a serious threat to public health. Consequently, substantial investment in research and development is directed towards discovering new antibiotics and alternative therapies, including bacteriophages, monoclonal antibodies, and immunotherapies, to combat resistant infections.

Global health trends and the epidemiology of infectious diseases heavily influence the anti-infectives market. The emergence of new pathogens, such as the novel coronavirus responsible for COVID-19, has underscored the critical need for robust anti-infective strategies. Large-scale vaccination programs, public health initiatives, and improved sanitation have played significant roles in controlling infectious diseases. However, the persistent threat of infections necessitates ongoing advancements in anti-infective drugs. Rapid progress in diagnostic technologies has also been instrumental, enabling quicker and more accurate detection of infections. This supports timely and appropriate treatment, reducing the burden of infectious diseases. Moreover, globalization, increased international travel, and trade have heightened the risk of cross-border transmission of infectious diseases, making a well-equipped arsenal of anti-infective drugs indispensable. Efforts to monitor and control outbreaks through advanced surveillance systems and international cooperation further highlight the market's dynamic nature and the need for continual innovation.

The growth in the anti-infectives market is driven by several factors. Technological advancements in drug discovery and development, such as high-throughput screening, artificial intelligence, and genomic studies, have accelerated the identification of potential anti-infective agents. These technologies allow for more precise targeting of pathogens, improving drug efficacy and reducing the likelihood of resistance development. The rising prevalence of chronic diseases and immunocompromised conditions, such as cancer, diabetes, and HIV, which increase susceptibility to infections, has heightened the demand for effective anti-infective therapies. Consumer behavior also plays a significant role, with increasing awareness and a proactive approach towards health and wellness contributing to market expansion. The expansion of healthcare infrastructure in emerging markets and improved access to healthcare services has further boosted the consumption of anti-infectives. Regulatory incentives, such as fast-track approvals and funding for antimicrobial resistance research, support the growth of this market. Collaborations between pharmaceutical companies, academic institutions, and government bodies are fostering innovation and development in the field, ensuring a continuous pipeline of new and effective anti-infective agents. Additionally, public-private partnerships and global health initiatives are crucial in addressing the unmet needs in the anti-infectives market, promoting the development and distribution of essential medicines to combat infectious diseases worldwide.

Select Competitors (Total 17 Featured) -

  • Allergan PLC
  • Bayer AG
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche AG
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis International AG
  • Pfizer, Inc.
  • Sanofi

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Global Economic Update
    • Anti-Infectives - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Drug-Resistant Infections Spurs Innovation
    • Technological Advancements in Drug Discovery and Development Accelerate Market Growth
    • Emergence of New Pathogens Expands Addressable Market Opportunity
    • Advances in Diagnostic Technologies Drive Adoption of Targeted Therapies
    • Globalization and Increased International Travel Throw the Spotlight on Cross-Border Transmission Risks
    • Growing Prevalence of Chronic Diseases and Immunocompromised Conditions Propels Demand
    • Regulatory Incentives and Fast-Track Approvals Sustain Growth of Anti-Infective Market
    • Public Health Initiatives and Vaccination Programs Enhances Control Measures
    • Rising Investment in Biotechnology and Pharmaceutical Research Spurs Development of Novel Compounds
    • Advancements in Nanotechnology for Drug Delivery Accelerate Demand for New Solutions
    • Impact of COVID-19 Pandemic on Anti-Infective Strategies Propels Market Awareness
    • Environmental and Ecological Changes Drive Adoption of New Anti-Infective Solutions
    • Shift Towards Sustainable and Eco-Friendly Drug Production Methods Impacts the Market
    • Demand for Multi-Functional and Combination Therapies Sustains Market Interest
    • Expansion of Telemedicine and Digital Health Platforms Drives Adoption of Anti-Infectives
    • Challenges of Antibiotic Overuse and Misuse: Here's the Story of the Growing Resistance Issue
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Anti-Infectives Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Anti-Infectives by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Anti-Infectives by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Anti-Infectives by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Anti-Viral Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Anti-Viral Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Anti-Viral Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Anti-Fungal Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Anti-Fungal Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Anti-Fungal Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Anti-Bacterial Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Anti-Bacterial Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Anti-Bacterial Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Anti-Infectives Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 14: USA Recent Past, Current & Future Analysis for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 15: USA Historic Review for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: USA 16-Year Perspective for Anti-Infectives by Type - Percentage Breakdown of Value Sales for Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 17: Canada Recent Past, Current & Future Analysis for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 18: Canada Historic Review for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: Canada 16-Year Perspective for Anti-Infectives by Type - Percentage Breakdown of Value Sales for Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs for the Years 2014, 2024 & 2030
  • JAPAN
    • Anti-Infectives Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 20: Japan Recent Past, Current & Future Analysis for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 21: Japan Historic Review for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: Japan 16-Year Perspective for Anti-Infectives by Type - Percentage Breakdown of Value Sales for Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs for the Years 2014, 2024 & 2030
  • CHINA
    • Anti-Infectives Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 23: China Recent Past, Current & Future Analysis for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 24: China Historic Review for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: China 16-Year Perspective for Anti-Infectives by Type - Percentage Breakdown of Value Sales for Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs for the Years 2014, 2024 & 2030
  • EUROPE
    • Anti-Infectives Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 26: Europe Recent Past, Current & Future Analysis for Anti-Infectives by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 27: Europe Historic Review for Anti-Infectives by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: Europe 16-Year Perspective for Anti-Infectives by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 29: Europe Recent Past, Current & Future Analysis for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 30: Europe Historic Review for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: Europe 16-Year Perspective for Anti-Infectives by Type - Percentage Breakdown of Value Sales for Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs for the Years 2014, 2024 & 2030
  • FRANCE
    • Anti-Infectives Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 32: France Recent Past, Current & Future Analysis for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: France Historic Review for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: France 16-Year Perspective for Anti-Infectives by Type - Percentage Breakdown of Value Sales for Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs for the Years 2014, 2024 & 2030
  • GERMANY
    • Anti-Infectives Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 35: Germany Recent Past, Current & Future Analysis for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Germany Historic Review for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: Germany 16-Year Perspective for Anti-Infectives by Type - Percentage Breakdown of Value Sales for Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 38: Italy Recent Past, Current & Future Analysis for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Italy Historic Review for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: Italy 16-Year Perspective for Anti-Infectives by Type - Percentage Breakdown of Value Sales for Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Anti-Infectives Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 41: UK Recent Past, Current & Future Analysis for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: UK Historic Review for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: UK 16-Year Perspective for Anti-Infectives by Type - Percentage Breakdown of Value Sales for Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 44: Spain Recent Past, Current & Future Analysis for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Spain Historic Review for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: Spain 16-Year Perspective for Anti-Infectives by Type - Percentage Breakdown of Value Sales for Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 47: Russia Recent Past, Current & Future Analysis for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Russia Historic Review for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Russia 16-Year Perspective for Anti-Infectives by Type - Percentage Breakdown of Value Sales for Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 50: Rest of Europe Recent Past, Current & Future Analysis for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Rest of Europe Historic Review for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Rest of Europe 16-Year Perspective for Anti-Infectives by Type - Percentage Breakdown of Value Sales for Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Anti-Infectives Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 53: Asia-Pacific Recent Past, Current & Future Analysis for Anti-Infectives by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 54: Asia-Pacific Historic Review for Anti-Infectives by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Asia-Pacific 16-Year Perspective for Anti-Infectives by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 56: Asia-Pacific Recent Past, Current & Future Analysis for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Asia-Pacific Historic Review for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Asia-Pacific 16-Year Perspective for Anti-Infectives by Type - Percentage Breakdown of Value Sales for Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Anti-Infectives Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 59: Australia Recent Past, Current & Future Analysis for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Australia Historic Review for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: Australia 16-Year Perspective for Anti-Infectives by Type - Percentage Breakdown of Value Sales for Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs for the Years 2014, 2024 & 2030
  • INDIA
    • Anti-Infectives Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 62: India Recent Past, Current & Future Analysis for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: India Historic Review for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: India 16-Year Perspective for Anti-Infectives by Type - Percentage Breakdown of Value Sales for Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 65: South Korea Recent Past, Current & Future Analysis for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: South Korea Historic Review for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: South Korea 16-Year Perspective for Anti-Infectives by Type - Percentage Breakdown of Value Sales for Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 68: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Rest of Asia-Pacific Historic Review for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: Rest of Asia-Pacific 16-Year Perspective for Anti-Infectives by Type - Percentage Breakdown of Value Sales for Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Anti-Infectives Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 71: Latin America Recent Past, Current & Future Analysis for Anti-Infectives by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 72: Latin America Historic Review for Anti-Infectives by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Latin America 16-Year Perspective for Anti-Infectives by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 74: Latin America Recent Past, Current & Future Analysis for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Latin America Historic Review for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Latin America 16-Year Perspective for Anti-Infectives by Type - Percentage Breakdown of Value Sales for Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 77: Argentina Recent Past, Current & Future Analysis for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Argentina Historic Review for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Argentina 16-Year Perspective for Anti-Infectives by Type - Percentage Breakdown of Value Sales for Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 80: Brazil Recent Past, Current & Future Analysis for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Brazil Historic Review for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Brazil 16-Year Perspective for Anti-Infectives by Type - Percentage Breakdown of Value Sales for Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 83: Mexico Recent Past, Current & Future Analysis for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Mexico Historic Review for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Mexico 16-Year Perspective for Anti-Infectives by Type - Percentage Breakdown of Value Sales for Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 86: Rest of Latin America Recent Past, Current & Future Analysis for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Rest of Latin America Historic Review for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Rest of Latin America 16-Year Perspective for Anti-Infectives by Type - Percentage Breakdown of Value Sales for Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Anti-Infectives Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 89: Middle East Recent Past, Current & Future Analysis for Anti-Infectives by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 90: Middle East Historic Review for Anti-Infectives by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Middle East 16-Year Perspective for Anti-Infectives by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 92: Middle East Recent Past, Current & Future Analysis for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Middle East Historic Review for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Middle East 16-Year Perspective for Anti-Infectives by Type - Percentage Breakdown of Value Sales for Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 95: Iran Recent Past, Current & Future Analysis for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Iran Historic Review for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Iran 16-Year Perspective for Anti-Infectives by Type - Percentage Breakdown of Value Sales for Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 98: Israel Recent Past, Current & Future Analysis for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Israel Historic Review for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Israel 16-Year Perspective for Anti-Infectives by Type - Percentage Breakdown of Value Sales for Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 101: Saudi Arabia Recent Past, Current & Future Analysis for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Saudi Arabia Historic Review for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Saudi Arabia 16-Year Perspective for Anti-Infectives by Type - Percentage Breakdown of Value Sales for Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 104: UAE Recent Past, Current & Future Analysis for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: UAE Historic Review for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: UAE 16-Year Perspective for Anti-Infectives by Type - Percentage Breakdown of Value Sales for Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 107: Rest of Middle East Recent Past, Current & Future Analysis for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Rest of Middle East Historic Review for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Rest of Middle East 16-Year Perspective for Anti-Infectives by Type - Percentage Breakdown of Value Sales for Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs for the Years 2014, 2024 & 2030
  • AFRICA
    • Anti-Infectives Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 110: Africa Recent Past, Current & Future Analysis for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Africa Historic Review for Anti-Infectives by Type - Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: Africa 16-Year Perspective for Anti-Infectives by Type - Percentage Breakdown of Value Sales for Anti-Viral Drugs, Anti-Fungal Drugs and Anti-Bacterial Drugs for the Years 2014, 2024 & 2030

IV. COMPETITION